The recent approvals of KRAS G12C inhibitors Adagrasib and Sotorasib for KRAS G12Cm NSCLC provide hope for therapeutic advances for a variety of KRAS mutations over the coming years, and many pan-RAS TKIs are in development. Here, KRAS is linked to non-small cell lung carcinoma.